<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00475904</url>
  </required_header>
  <id_info>
    <org_study_id>EPC2007-02</org_study_id>
    <nct_id>NCT00475904</nct_id>
  </id_info>
  <brief_title>A Comparison of EpiCept™ NP-1 Topical Cream vs. Oral Gabapentin in Postherpetic Neuralgia (PHN)</brief_title>
  <official_title>A Phase II, Double-Blind, Randomized, Placebo-Controlled Non-inferiority Trial of EpiCept™ NP-1 Topical Cream (2% Ketamine / 4% Amitriptyline) vs. Oral Gabapentin in Postherpetic Neuralgia (PHN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EpiCept Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EpiCept Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare EpiCept™ NP-1 Topical Cream (2% ketamine / 4%
      amitriptyline) vs. Oral Gabapentin in the treatment of Postherpetic Neuralgia (PHN)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II, multicenter, double-blind, randomized, placebo-controlled, parallel group
      study of NP-1 and oral gabapentin in approximately 500 patients with PHN. Adult patients with
      pain resulting from PHN and meeting all other eligibility requirements will be screened for 7
      days to determine their average daily pain intensity. Qualifying patients will be randomized
      on a 2:2:1 basis to NP-1, oral gabapentin, or placebo. The treatment period will be 4-Weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pain Scores Comparing NP-1 Cream vs. Placebo Cream for Treatment of the Pain of Post Herpetic Neuralgia(PHN)From Baseline to 28 Days.</measure>
    <time_frame>baseline and 28 days</time_frame>
    <description>Difference in pain scores between NP-1 cream vs. placebo cream for the treatment of the pain of PHN. Baseline pain scores were compared to the pain scores after 28 days of treatment. Pain scores were rated on a 11 point numerical rating scale (0-10) where 0 was no pain and 10 was worst possible pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Pain Intensity From Baseline to 28 Days of Treatment, Comparison Between NP-1 Topical Cream and Oral Gabapentin</measure>
    <time_frame>baseline to 28 Days</time_frame>
    <description>Change in pain intensity scores between NP-1 cream vs. oral gabapentin for the treatment of the pain of PHN. Baseline pain scores were compared to the pain scores after 28 days of treatment. Pain scores were rated on a 11 point numerical rating scale (0-10) where 0 was no pain and 10 was worst possible pain.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">360</enrollment>
  <condition>Post Herpetic Neuralgia</condition>
  <condition>PHN</condition>
  <condition>Neuropathy</condition>
  <condition>Nerve Pain</condition>
  <arm_group>
    <arm_group_label>amitriptyline 4% ketamine 2% cream, placebo capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Np-1 cream and placebo gabapentin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>gabapentin capsules, placebo cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>gabapentin caps and placebo cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo cream and capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo cream and capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EpiCept-NP-1 Cream</intervention_name>
    <description>ketamine 4% amitriptyline 2% cream, twice daily for 4 weeks</description>
    <arm_group_label>amitriptyline 4% ketamine 2% cream, placebo capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin Capsules</intervention_name>
    <description>1800mg/day capsules for 4 weeks</description>
    <arm_group_label>gabapentin capsules, placebo cream</arm_group_label>
    <other_name>gabapentin, neurontin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo cream and caps</description>
    <arm_group_label>placebo cream and capsules</arm_group_label>
    <other_name>vehicle cream, placebo capsules</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with pain for ≥ 3 months following onset of a herpes zoster rash

        Exclusion Criteria:

          -  Clinically significant intercurrent illness (e.g., endocrine, cardiac, hepatic, renal,
             neurologic, hematologic, skeletal) that the investigator determines could interfere
             with the efficacy or safety assessments.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert H Dworkin, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Multiple Centers</name>
      <address>
        <city>New Delhi</city>
        <zip>110016</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2007</study_first_submitted>
  <study_first_submitted_qc>May 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2007</study_first_posted>
  <results_first_submitted>April 20, 2011</results_first_submitted>
  <results_first_submitted_qc>June 9, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 6, 2011</results_first_posted>
  <last_update_submitted>July 25, 2011</last_update_submitted>
  <last_update_submitted_qc>July 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Stephane Allard, Chief Medical Officer</name_title>
    <organization>EpiCept Corporation</organization>
  </responsible_party>
  <keyword>Post Herpetic Neuralgia</keyword>
  <keyword>PHN</keyword>
  <keyword>Neuropathy</keyword>
  <keyword>Nerve Pain</keyword>
  <keyword>Topical</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Neuralgia, Postherpetic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Amitriptyline</mesh_term>
    <mesh_term>Amitriptyline, perphenazine drug combination</mesh_term>
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Amitriptyline 4% Ketamine 2% Cream, Placebo Capsules</title>
          <description>amitriptyline 4% ketamine 2% cream 4grams applied twice daily to affected area, placebo capsules taken orally 3 times daily</description>
        </group>
        <group group_id="P2">
          <title>Gabapentin Capsules, Placebo Cream</title>
          <description>oral gabapentin capsules 600mg three times daily and placebo cream applied 4 grams twice daily</description>
        </group>
        <group group_id="P3">
          <title>Placebo Cream and Capsules</title>
          <description>placebo NP-1 cream 4gms applied twice daily and placebo gabapentin capsules, taken orally 3 times daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="144"/>
                <participants group_id="P3" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="131"/>
                <participants group_id="P3" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Amitriptyline 4% Ketamine 2% Cream, Placebo Capsules</title>
          <description>amitriptyline 4% ketamine 2% cream 4grams applied twice daily to affected area, placebo capsules taken orally 3 times daily</description>
        </group>
        <group group_id="B2">
          <title>Gabapentin Capsules, Placebo Cream</title>
          <description>oral gabapentin capsules 600mg three times daily and placebo cream applied 4 grams twice daily</description>
        </group>
        <group group_id="B3">
          <title>Placebo Cream and Capsules</title>
          <description>placebo NP-1 cream 4gms applied twice daily and placebo gabapentin capsules, taken orally 3 times daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="140"/>
            <count group_id="B2" value="144"/>
            <count group_id="B3" value="76"/>
            <count group_id="B4" value="360"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.3" spread="16.04"/>
                    <measurement group_id="B2" value="53.2" spread="15.53"/>
                    <measurement group_id="B3" value="53.2" spread="16.47"/>
                    <measurement group_id="B4" value="52.5" spread="15.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="76"/>
                    <measurement group_id="B4" value="360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Pain Scores Comparing NP-1 Cream vs. Placebo Cream for Treatment of the Pain of Post Herpetic Neuralgia(PHN)From Baseline to 28 Days.</title>
        <description>Difference in pain scores between NP-1 cream vs. placebo cream for the treatment of the pain of PHN. Baseline pain scores were compared to the pain scores after 28 days of treatment. Pain scores were rated on a 11 point numerical rating scale (0-10) where 0 was no pain and 10 was worst possible pain.</description>
        <time_frame>baseline and 28 days</time_frame>
        <population>This analysis was performed for the Intent To Treat (ITT) population using the ast Observation Carried Forward (LOCF) approach.</population>
        <group_list>
          <group group_id="O1">
            <title>Amitriptyline 4% Ketamine 2% Cream, Placebo Capsules</title>
            <description>amitriptyline 4% ketamine 2% cream 4grams applied twice daily to affected area, placebo capsules taken orally 3 times daily</description>
          </group>
          <group group_id="O2">
            <title>Gabapentin Capsules, Placebo Cream</title>
            <description>oral gabapentin capsules 600mg three times daily and placebo cream applied 4 grams twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo Cream and Capsules</title>
            <description>placebo NP-1 cream 4gms applied twice daily and placebo gabapentin capsules, taken orally 3 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain Scores Comparing NP-1 Cream vs. Placebo Cream for Treatment of the Pain of Post Herpetic Neuralgia(PHN)From Baseline to 28 Days.</title>
          <description>Difference in pain scores between NP-1 cream vs. placebo cream for the treatment of the pain of PHN. Baseline pain scores were compared to the pain scores after 28 days of treatment. Pain scores were rated on a 11 point numerical rating scale (0-10) where 0 was no pain and 10 was worst possible pain.</description>
          <population>This analysis was performed for the Intent To Treat (ITT) population using the ast Observation Carried Forward (LOCF) approach.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.424" lower_limit="2.07" upper_limit="2.78"/>
                    <measurement group_id="O2" value="2.471" lower_limit="2.17" upper_limit="2.77"/>
                    <measurement group_id="O3" value="1.877" lower_limit="1.43" upper_limit="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>In the initial analysis, the efficacy of the test treatment NP-1 cream was compared with placebo using an analysis of variance (ANOVA). The analysis was conducted using the ITT population to compare the mean changes in pain scores from baseline to endpoint for the 2 treatments; the LOCF approach was employed for patients who did not complete the trial.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0441</p_value>
            <p_value_desc>a priori threshold for statistical significance was p&lt;0.05</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.547</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2709</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Pain Intensity From Baseline to 28 Days of Treatment, Comparison Between NP-1 Topical Cream and Oral Gabapentin</title>
        <description>Change in pain intensity scores between NP-1 cream vs. oral gabapentin for the treatment of the pain of PHN. Baseline pain scores were compared to the pain scores after 28 days of treatment. Pain scores were rated on a 11 point numerical rating scale (0-10) where 0 was no pain and 10 was worst possible pain.</description>
        <time_frame>baseline to 28 Days</time_frame>
        <population>Intent To Treat (ITT) population using the Last Observation Carried Forward) LOCF imputation technique</population>
        <group_list>
          <group group_id="O1">
            <title>Amitriptyline 4% Ketamine 2% Cream, Placebo Capsules</title>
            <description>amitriptyline 4% ketamine 2% cream 4grams applied twice daily to affected area, placebo capsules taken orally 3 times daily</description>
          </group>
          <group group_id="O2">
            <title>Gabapentin Capsules, Placebo Cream</title>
            <description>oral gabapentin capsules 600mg three times daily and placebo cream applied 4 grams twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo Cream and Capsules</title>
            <description>placebo NP-1 cream 4gms applied twice daily and placebo gabapentin capsules, taken orally 3 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain Intensity From Baseline to 28 Days of Treatment, Comparison Between NP-1 Topical Cream and Oral Gabapentin</title>
          <description>Change in pain intensity scores between NP-1 cream vs. oral gabapentin for the treatment of the pain of PHN. Baseline pain scores were compared to the pain scores after 28 days of treatment. Pain scores were rated on a 11 point numerical rating scale (0-10) where 0 was no pain and 10 was worst possible pain.</description>
          <population>Intent To Treat (ITT) population using the Last Observation Carried Forward) LOCF imputation technique</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.424" lower_limit="2.07" upper_limit="2.7"/>
                    <measurement group_id="O2" value="2.471" lower_limit="2.17" upper_limit="2.77"/>
                    <measurement group_id="O3" value="1.877" lower_limit="1.43" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>the primary hypothesis of this study was that NP-1 topical cream (amitriptyline 4%/ketamine 2%) administered twice daily in doses of 4 gm for 4 weeks is not inferior to the standard treatment (oral gabapentin 600 mg 3 times daily) for relieving the pain of adult patients with PHN.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To conclude that the NP-1 was not inferior to gabapentin, the upper limit of the 2-sided 90% CI for the difference between treatments for the endpoint mean pain score was required to be below the non-inferiority margin of 0.70.</non_inferiority_desc>
            <p_value>0.8409</p_value>
            <p_value_desc>To conclude that the NP-1 was not inferior to gabapentin, the upper limit of the 2-sided 90% CI for the difference between treatments for the endpoint mean pain score was required to be below the non-inferiority margin of 0.70.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.046</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>.2311</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.33</ci_lower_limit>
            <ci_upper_limit>0.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Amitriptyline 4% Ketamine 2% Cream, Placebo Capsules</title>
          <description>amitriptyline 4% ketamine 2% cream 4grams applied twice daily to affected area, placebo capsules taken orally 3 times daily</description>
        </group>
        <group group_id="E2">
          <title>Gabapentin Capsules, Placebo Cream</title>
          <description>oral gabapentin capsules 600mg three times daily and placebo cream applied 4 grams twice daily</description>
        </group>
        <group group_id="E3">
          <title>Placebo Cream and Capsules</title>
          <description>placebo NP-1 cream 4gms applied twice daily and placebo gabapentin capsules, taken orally 3 times daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="140"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>EpiCept Corporation</organization>
      <phone>914-606-3500</phone>
      <email>sallard@epicept.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

